Jpmorgan Chase & Co »

Aeglea Biotherapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2023-12-31 $882 41 21.51
2023-09-30 $501 41 12.24

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Trust Fund (SPY)
Nvidia Corporation Common (NVDA)
Meta Platforms Common (META)
Unitedhealth Group Common (UNH)
Vanguard Total Intl Bond Etf Fund (BNDX)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Mastercard Incorporated Common (MA)
Alphabet Common (GOOGL)
Abbvie Common (ABBV)
Vanguard Total Bond Market Fund (BND)
Tesla Common (TSLA)

View all positions for Jpmorgan Chase & Co

Top funds holding Aeglea Biotherapeutics

Perceptive Advisors
VR Adviser
Commodore Capital
venBio Select Advisor
Cormorant Asset Management
EcoR1 Capital
Franklin Resources
BVF
Wellington Management Company
Citadel Advisors
Braidwell
Global Endowment Management
First Turn Management
Fairmount Funds Management
Boxer Capital

View all funds holding Aeglea Biotherapeutics